Company intelligence / Profile preview
Tuojie Biotech
Shanghai, Shanghai, Chinatuojiebiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tuojie Biotech is advancing multiple small molecule and oligonucleotide drugs for oncology, cardiovascular, metabolic, and immune disorders. Pipeline includes CDK inhibitors for cancer and inflammatory disorders, LPAR1 antagonists for metabolic/inflammatory/fibrotic disorders, mineralocorticoid receptor antagonists for cardiovascular disease, and a GLP-1/GIP dual agonist for obesity, with some candidates in Phase 1. Clinical results have yet to be published for most pipeline assets.
- Therapeutic areas
- ImmunologyEndocrinologyMetabolic DisordersInfectious DiseasesCardiovascularOtherOncology
- Modalities
- Small moleculeOligonucleotidePeptidesMonoclonal antibodySynthetic peptideBiological products
- Industry
- Biotech
02
Drug pipeline
26 assets25 more assets in the full pipeline.
Beyond the preview
Go deeper on Tuojie Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tuojie Biotech.